12:00 AM
 | 
Nov 15, 2004
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion
Angiotech (TSE:ANP; ANPI) Dundee David Martin Downgrade Neutral (from market outperform)
Martin downgraded the cardiovascular company's stock because of recent price appreciation. On NASDAQ, ANPI closed Friday at $20, down $0.37 on the week.
Genta (GNTA) Needham Mark Monane Downgrade Hold (from buy)
Monane said he's "cautious" about whether the company will be able to seek FDA approval of Genasense to treat chronic lymphocytic leukemia (CLL) based on data from a single Phase III trial. Last week, the company said Genasense met the primary endpoint but missed...

Read the full 558 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >